Nephrol Dial Transplant (1999) 14: 2903-2906
© 1999 European Renal Association-European Dialysis and Transplant Association
Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients
1 Departments of Nephrology and 2 Biochemistry, Necker Hospital, Paris, France
Correspondence and offprint requests to: Professor Paul Jungers MD, Department of Nephrology, Necker Hospital, 149 rue de Sèvres, F-75015 Paris, France.
Background. Moderate hyperhomocysteinaemia, as occurs in chronic renal failure patients, is an established independent risk factor for atherosclerotic arterial occlusive accidents, the incidence of which is abnormally high in such patients. Folic acid supplementation has been shown to reduce plasma homocysteine level in end-stage renal disease patients treated with haemodialysis or peritoneal dialysis, but its long-term effects in predialysis patients had not been assessed.
Methods. We prospectively treated a total of 78 predialysis patients with folic acid for at least 1 year (range 12–74 months) together with oral pyridoxine and vitamin B12 supplements. Of the patients, 67 received 5 mg folic acid three times per week, whereas the other 11 patients who were treated with recombinant erythropoietin received 5 mg/day. Plasma fasting total homocysteine concentration was determined at baseline, after 3 months and at the end of follow-up.
Results. Mean (±SD) plasma total homocysteine level decreased from 21.2±6.4 µmol/l at baseline to 14.2±4.6 at 3 months and remained at 12.8±3.7 µmol/l at the end of follow-up (average duration 2.8 years), whereas plasma creatinine rose from 268±129 to 399±234 µmol/l. Mean plasma folate concentration rose from 19±12 to 47±13 nmol/l and mean plasma vitamin B12 rose from 237±119 to 347±191 pmol/l from baseline to end of follow-up.
Conclusions. Moderate folic acid supplementation (2.15 mg/day) allows a substantial (40% as a mean) and sustained (up to 6 years) reduction of plasma total homocysteine level in predialysis uraemic patients without any detectable side effect. Folic acid supplementation may thus contribute to lower the risk of accelerated atherosclerosis in such patients.
Keywords: chronic renal failure; folic acid; hyperhomocysteinaemia; predialysis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. P. S. Shantha, A. A. Kumar, E. Bhaskar, K. Sivagnanam, D. Srinivasan, M. Sundaresan, P. Arthur, and G. Abraham Hypertensive retinal changes, a screening tool to predict microalbuminuria in hypertensive patients: a cross-sectional study Nephrol. Dial. Transplant., January 6, 2010; (2010) gfp726v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Jamison, P. Hartigan, J. S. Kaufman, D. S. Goldfarb, S. R. Warren, P. D. Guarino, J. M. Gaziano, and For the Veterans Affairs Site Investigators Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease: A Randomized Controlled Trial JAMA, September 12, 2007; 298(10): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L Jamison, P. Hartigan, J M. Gaziano, S. P Fortmann, D. S Goldfarb, J. A Haroldson, J. Kaufman, P. Lavori, K. S McCully, and K. Robinson Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study Clinical Trials, October 1, 2004; 1(5): 451 - 460. [Abstract] [PDF]
|
|
|
|
 |
|
 H. M. Sadeghi, G. W. Stone, C. L. Grines, R. Mehran, S. R. Dixon, A. J. Lansky, M. Fahy, D. A. Cox, E. Garcia, J. E. Tcheng, et al. Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction Circulation, December 2, 2003; 108(22): 2769 - 2775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Leoncini, F. Viazzi, D. Parodi, S. Vettoretti, E. Ratto, M. Ravera, C. Tomolillo, M. Del Sette, G. P. Bezante, G. Deferrari, et al. Mild Renal Dysfunction and Subclinical Cardiovascular Damage in Primary Hypertension Hypertension, July 1, 2003; 42(1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Amann, C. Ritz, M. Adamczak, and E. Ritz Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol. Dial. Transplant., April 1, 2003; 18(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F.E. Mann, H. C. Gerstein, J. Pogue, J. Bosch, S. Yusuf, and for the HOPE Investigators Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial Ann Intern Med, April 17, 2001; 134(8): 629 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jungers, G. Choukroun, Z. Oualim, C. Robino, A.-T. Nguyen, and N.-K. Man Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients Nephrol. Dial. Transplant., February 1, 2001; 16(2): 307 - 312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bennett-Richards, M. Kattenhorn, A. Donald, G. Oakley, Z. Varghese, L. Rees, and J.E. Deanfield Does Oral Folic Acid Lower Total Homocysteine Levels and Improve Endothelial Function in Children With Chronic Renal Failure? Circulation, April 16, 2002; 105(15): 1810 - 1815. [Abstract] [Full Text] [PDF]
|
|